Development of a Compact, Time-Efficient and Safe Medical Diagnostics Machine

ended

Current tissue processors on the market take up to 24 hours to process samples for diagnosis and leave the operator exposed to chemicals. They also use different kinds of chemicals, in large volumes, which leads to cross contamination of chemicals and samples. This results in more plastic packaging to dispose of, making the process both costly and environmental unfriendly. Our company, DIAPATH SpA, is developing an innovative solution to these problems, Origin. DIAPATH has been in the tissue processing industry since 1997 and currently has a turnover of €16.8 Million and 97 employees. Origin reduces the number of processing steps, and reduces the number of chemicals used. The operator will be safeguarded from chemical exposure. Our value proposition is, less operating costs due to reduced chemicals and packaging, faster diagnosis and results for patients. Our target users are Hospitals and Diagnostics Laboratories. The current global diagnostics market is estimated at €243.59 Million and expected to reach €378 Million by year 2025. Our entry point for our innovation will be the European market, where we already have significant market share. We will be using our extensive distribution chain to bring our innovation to international markets. Our innovation is currently at prototype stage with a compact functional machine tested in relevant environment. Further validation and tests remain to be done to bring it to market. This innovation will grow our market share to 30% and increase our turnover to €60million by 2023. It will also create 29 new jobs.